Grahame Cook 

Non-Executive Chairman

Michael Flynn     

Chief Executive Officer

Dr Flynn became Chief Executive Officer of Sinclair Pharma in August 2000 following a management buy-in of Sinclair Pharmaceuticals Limited, which he led. Between 1998 and 2000, Dr Flynn privately acquired the rights to a portfolio of products, which he brought to the Group. From June to November 1998, Dr Flynn was acting Chief Executive Officer of Cortecs Group plc where he held the position of President between 1992 and June 1998 and of Director between 1986 and 1992. Between 1976 and 1986, he was Medical Director and President of Technology International Limited, a contract research organisation that Dr Flynn co-founded. Prior to 1976, Dr Flynn had worked as Senior Medical Advisor to Crookes Laboratories Limited, established Duphar Limited in the UK and spent approximately five years in the Clinical Research Department of Philips Duphar in Holland. Dr Flynn has spent over 30 years in the pharmaceutical industry and has served on the Board of Directors of approximately 30 private companies involved in the healthcare sector. Dr Flynn was elected a fellow by Distinction of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians in 2001 and qualified as a physician from Kings College Hospital, London. As noted in the Chief Executive’s Review, Dr Flynn will be retiring at the next AGM.

Jerry Randall    

Chief Financial Officer

Mr Randall became Chief Financial Officer of the Company in August 2000 when he completed the management buy-in with Dr Flynn. Before joining Sinclair Pharma,Mr Randall worked in corporate finance, setting up and running the Bristol office of Gambit Corporate Finance. Prior to that, Mr Randall had been involved in two other buy-ins and acted as advisor to both private and quoted companies between 1993 and 2000, in both the capacity as nominated advisor and in practice with KPMG. During this period, Mr Randall was involved in a number of flotations and transactions on the Official List, Unlisted Securities Market and the Alternative Investment Market, as well as raising private equity. Mr. Randall qualified as a chartered accountant with KPMG in 1990. Mr Randall is also a Non-Executive Director of Silence Therapeutics plc.

Penny Freer   

Senior Independent Director

Ms Freer joined the Board in January 2006. She has over 20 years experience in investment banking advising companies on a wide variety of issues including their interaction with the capital markets. From 2000, Ms Freer was Head of Equities for Robert W. Baird in London, previously she was responsible for Credit Lyonnais Securities’ small and mid cap equities activities. In 2004 she co‑founded Capital Markets Group, an FSA authorised corporate advisory and investor relations business. She is currently a Non‑Executive Director of Empresaria Group plc.

Jean-Charles Tschudin     

Non-Executive Director

Mr Tschudin joined the Board in November 2007. He has extensive experience in the pharmaceutical industry at a senior executive level on three continents and was recently President and Chief Operating Officer of Yamanouchi Europe, the largest Japanese company in Europe (now Astellas). He has also held senior positions at Johnson & Johnson, Schering-Plough, Syntex and Cardinal Health. Mr Tschudin is currently Non-Executive Director of SkyePharma plc, is a Chartered Director and he also consults for the pharma industry.